The Attorney General of Maine, Aaron M. Frey, responded to a federal lawsuit initiated by the Trump administration against the Maine Department of Education regarding Title IX.
Attorney General Aaron M. Frey announced his participation in a multistate lawsuit against former President Donald J. Trump and various Trump Administration officials.
Attorney General Aaron M. Frey has joined a coalition to file a lawsuit against the U.S. Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy, Jr.
Attorney General Aaron M. Frey, along with a coalition of 22 other attorneys general, has secured a preliminary injunction against the Trump administration's policy to freeze federal funds.
Attorney General Aaron M. Frey, along with a coalition of 21 other attorneys general, has successfully secured a nationwide preliminary injunction in the case of Massachusetts v. NIH.
Attorney General Aaron M. Frey, along with 21 other attorneys general, has initiated legal action against the Trump Administration, the Department of Health and Human Services, and the National Institutes of Health (NIH).
Attorney General Aaron M. Frey has aligned with a coalition of 12 attorneys general to issue a statement concerning the U.S. Department of the Treasury's decision to allow Elon Musk and his "Department of Government Efficiency" (DOGE) staffers...
Attorney General Aaron M. Frey, along with 14 other attorneys general, issued a joint statement today in response to the Trump Administration's recent Executive Order concerning gender-affirming care.
Attorney General Aaron M. Frey, along with 18 other states, has initiated legal action against President Donald Trump's executive order that aims to end birthright citizenship in the United States.
Attorney General Aaron Frey has filed a lawsuit against several major fossil fuel companies, accusing them of misleading the public in Maine about climate change.
Attorney General Aaron M. Frey has announced two significant cooperation agreements and settlements in a multistate litigation against generic drug manufacturers.
